WallStreetZenWallStreetZen

NASDAQ: RPRX
Royalty Pharma PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their RPRX stock forecasts and price targets.

Forecast return on equity

Is RPRX forecast to generate an efficient return?

Company
31.45%
Industry
170.81%
Market
69.88%
RPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RPRX forecast to generate an efficient return on assets?

Company
17.48%
Industry
48.33%
RPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RPRX earnings per share forecast

What is RPRX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$4.44+79.76%
Avg 2 year Forecast
$5.21+110.83%
Avg 3 year Forecast
$5.48+121.66%
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

RPRX revenue forecast

What is RPRX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$3.0B+31.05%
Avg 2 year Forecast
$3.2B+41.49%
Avg 3 year Forecast
$3.5B+54.96%
RPRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RPRX earnings growth forecast

How is RPRX forecast to perform vs Biotechnology companies and vs the US market?

Company
43.19%
Industry
24.91%
Market
20.63%
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
RPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

RPRX revenue growth forecast

How is RPRX forecast to perform vs Biotechnology companies and vs the US market?

Company
19.37%
Industry
133.62%
Market
9.87%
RPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RPRX$32.82N/AN/A
SMMT$24.61$36.67+48.99%Strong Buy
BNTX$94.50$149.19+57.87%Strong Buy
UTHR$308.07$371.00+20.43%Buy
GMAB$19.31$36.33+88.16%Strong Buy
View Top Biotech Stocks

Royalty Pharma Stock Forecast FAQ

What is RPRX's earnings growth forecast for 2025-2027?

(NASDAQ: RPRX) Royalty Pharma's forecast annual earnings growth rate of 43.19% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.91%, and it is also forecast to beat the US market's average forecast earnings growth rate of 20.63%.

Royalty Pharma's earnings in 2025 is $1,092,554,000.On average, 4 Wall Street analysts forecast RPRX's earnings for 2025 to be $2,496,346,794, with the lowest RPRX earnings forecast at $2,293,940,298, and the highest RPRX earnings forecast at $2,721,242,902. On average, 4 Wall Street analysts forecast RPRX's earnings for 2026 to be $2,927,866,201, with the lowest RPRX earnings forecast at $2,501,969,197, and the highest RPRX earnings forecast at $3,570,225,708.

In 2027, RPRX is forecast to generate $3,078,265,473 in earnings, with the lowest earnings forecast at $2,856,180,567 and the highest earnings forecast at $3,300,350,379.

If you're new to stock investing, here's how to buy Royalty Pharma stock.

What is RPRX's revenue growth forecast for 2025-2027?

(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 19.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 133.62%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.87%.

Royalty Pharma's revenue in 2025 is $2,263,845,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,668,042,060,783, with the lowest RPRX revenue forecast at $1,651,247,381,708, and the highest RPRX revenue forecast at $1,684,837,302,099. On average, 2 Wall Street analysts forecast RPRX's revenue for 2026 to be $1,800,947,789,011, with the lowest RPRX revenue forecast at $1,744,214,934,668, and the highest RPRX revenue forecast at $1,857,681,205,595.

In 2027, RPRX is forecast to generate $1,972,307,378,197 in revenue, with the lowest revenue forecast at $1,957,741,981,788 and the highest revenue forecast at $1,986,872,774,606.

What is RPRX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: RPRX) forecast ROA is 17.48%, which is lower than the forecast US Biotechnology industry average of 48.33%.

What is RPRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RPRX) Royalty Pharma's current Earnings Per Share (EPS) is $2.47. On average, analysts forecast that RPRX's EPS will be $4.44 for 2025, with the lowest EPS forecast at $4.08, and the highest EPS forecast at $4.84. On average, analysts forecast that RPRX's EPS will be $5.21 for 2026, with the lowest EPS forecast at $4.45, and the highest EPS forecast at $6.35. In 2027, RPRX's EPS is forecast to hit $5.48 (min: $5.08, max: $5.87).

What is RPRX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: RPRX) forecast ROE is 31.45%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.